ThetaOwl

REGN AI Analysis Reports

Regeneron Pharmaceuticals, Inc.

DirectionalTheta GangFlowEarnings
Directional
March 31, 2026

Neutral-to-bullish with a multi-week pinning bias toward the $745-$760 max pain cluster. Confidence: 7.5/10. Spot is 3.7

Confidence:6/10

Primary thesis is a multi-week pin toward the $745-$760 max pain cluster, supported by positive GEX/DEX. Invalidation is a close below $730. The regime favors selling premium (puts/put spreads) below

Based on market close March 31, 2026
Theta Gang
March 31, 2026

Attractiveness: 6/10

Confidence:3.5/10

Sell put spreads below OI support, favoring 30-45 DTE.

Based on market close March 31, 2026
Flow
March 31, 2026

Mixed

Confidence:2.5/10

Net premium consistently positive >$5M with sustained call buying at/near spot

Based on market close March 31, 2026
Earnings
March 31, 2026

Earnings expected ~April 29 (inferred). IV elevated for May 1 expiration (49.3%), creating crush opportunity. Historical

Confidence:6.5/10

IV term structure shows clear kink at May 1 expiration (49.3% vs 44.3% before), confirming earnings timing. Historical 75% beat rate with average 27% surprise magnitude.

Based on market close March 31, 2026

Browse AI-powered options reports for REGN, including directional, theta gang, flow, and earnings analysis. Each report features regime classification, key price levels, strategy viability ratings, and specific trade recommendations updated daily.

REGN AI Analysis Reports | ThetaOwl